Pair Name | Pterostilbene, Vorinostat | ||
Phytochemical Name | Pterostilbene (PubChem CID: 5281727 ) | ||
Anticancer drug Name | Vorinostat (PubChem CID: 5311 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Pterostilbene, Vorinostat | |||
Disease Info | [ICD-11: 2C82] | Prostate cancer | Investigative | |
Gene Regulation | Down-regulation | Expression | HIF1A | hsa3091 |
Down-regulation | Expression | IL1B | hsa3553 | |
Down-regulation | Expression | MTA1 | hsa9112 | |
Down-regulation | Expression | VEGFA | hsa7422 | |
In Vitro Model | LNCaP | Prostate carcinoma | Homo sapiens (Human) | CVCL_0395 |
In Vivo Model | Female C57BL/6J mouse homozygous with "floxed" allele of Pten gene were used in this study. | |||
Result | Our study provides preclinical evidence that Pter/SAHA combination treatment inhibits MTA1/HIF-1α tumor-promoting signaling in PCa. The beneficial outcome of combinatorial strategy using a natural agent and an approved drug for higher efficacy and less toxicity supports further development of MTA1-targeted therapies in PCa. |
No. | Title | Href |
---|---|---|
1 | Targeting MTA1/HIF-1α signaling by pterostilbene in combination with histone deacetylase inhibitor attenuates prostate cancer progression. Cancer Med. 2017 Nov;6(11):2673-2685. doi: 10.1002/cam4.1209. | Click |